Ricardo De Lumpa

Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2020, Leukemia & lymphoma.